SEC Form 4 · accession 0000891293-16-000135
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Plunkett
Officer — EVP, Chief Business Officer
Period of report
Mar 21, 2016
Accepted (ET)
Mar 23, 2016 · 6:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 21, 2016 | F | 63,874 | $0.5482 | D | 526,210 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld by CTIC to satisfy minimum tax withholding obligations on the vesting of restricted stock.